NO931561L - Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar - Google Patents

Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar

Info

Publication number
NO931561L
NO931561L NO93931561A NO931561A NO931561L NO 931561 L NO931561 L NO 931561L NO 93931561 A NO93931561 A NO 93931561A NO 931561 A NO931561 A NO 931561A NO 931561 L NO931561 L NO 931561L
Authority
NO
Norway
Prior art keywords
treatment
inhibitors
scars
inflammation
plasminogen activators
Prior art date
Application number
NO93931561A
Other languages
English (en)
Norwegian (no)
Other versions
NO931561D0 (no
Inventor
Eckhard Schueler
Juergen Roemisch
Eric-Paul Paques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO931561D0 publication Critical patent/NO931561D0/no
Publication of NO931561L publication Critical patent/NO931561L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO93931561A 1992-04-30 1993-04-29 Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar NO931561L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (de) 1992-04-30 1992-04-30 Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen

Publications (2)

Publication Number Publication Date
NO931561D0 NO931561D0 (no) 1993-04-29
NO931561L true NO931561L (no) 1993-11-01

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931561A NO931561L (no) 1992-04-30 1993-04-29 Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar

Country Status (16)

Country Link
EP (1) EP0567816A1 (ja)
JP (1) JPH069425A (ja)
KR (1) KR930021179A (ja)
CN (1) CN1080873A (ja)
AU (1) AU3822993A (ja)
CA (1) CA2095207A1 (ja)
CZ (1) CZ76893A3 (ja)
DE (1) DE4214215A1 (ja)
HU (1) HUT65755A (ja)
IL (1) IL105521A0 (ja)
MX (1) MX9302519A (ja)
NO (1) NO931561L (ja)
PL (1) PL298748A1 (ja)
SK (1) SK41593A3 (ja)
UY (1) UY23572A1 (ja)
ZA (1) ZA933023B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DE69435342D1 (de) 1993-07-19 2011-05-05 Angiotech Pharm Inc Anti-Angiogene Mittel und Verfahren zu deren Verwendung
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6344189B1 (en) * 1998-04-01 2002-02-05 Biotech Australia Pty., Ltd. Use of protease inhibitors for treating skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
DK1173198T3 (da) 1999-04-29 2004-04-13 Ista Pharmaceuticals Inc Anvendelse af en bestemt hyaluronidase til eliminering af ar på, uigennemsigtighed og uklarhed på hornhinden
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (ja) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション クライアントサーバーシステム、オブジェクトのプール方法および記憶媒体
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
JP2001247458A (ja) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd トラネキサム酸亜鉛化合物を含む糖尿病治療剤
EP1365798B1 (en) 2000-09-29 2009-12-30 Viron Therapeutics, Inc. Use of serp-1 in combination with an immunosuppressant for treating arthritis
ES2243556T3 (es) 2000-10-16 2005-12-01 Conor Medsystems, Inc. Dispositivo medico expandible para proporcionar un agente beneficioso.
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
AU2009207394B2 (en) * 2008-01-21 2015-01-22 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
TWI763960B (zh) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 一種預防或治療骨關節炎的方法及藥物
CN118557734A (zh) * 2024-07-24 2024-08-30 中山大学中山眼科中心 Serpinb2抑制剂在制备用于治疗湿性年龄相关性黄斑变性药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
AU625018B2 (en) * 1989-12-20 1992-06-25 Biotech Australia Pty Limited Variants of pai-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
HU9301272D0 (en) 1993-07-28
ZA933023B (en) 1994-10-31
IL105521A0 (en) 1993-08-18
PL298748A1 (en) 1993-12-27
DE4214215A1 (de) 1993-11-04
KR930021179A (ko) 1993-11-22
AU3822993A (en) 1993-11-04
NO931561D0 (no) 1993-04-29
EP0567816A1 (de) 1993-11-03
CA2095207A1 (en) 1993-10-31
CZ76893A3 (en) 1994-01-19
SK41593A3 (en) 1993-11-10
CN1080873A (zh) 1994-01-19
UY23572A1 (es) 1993-05-04
HUT65755A (en) 1994-07-28
JPH069425A (ja) 1994-01-18
MX9302519A (es) 1993-10-01

Similar Documents

Publication Publication Date Title
NO931561L (no) Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
Bunning et al. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes
IL122116A0 (en) Polypeptide comprising kunitz-type serine protease inhibitor
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
NO303116B1 (no) Forbindelser som kan anvendes for behandling av allergiske sykdommer og betennelsessykdommer, anvendelse av dem, samt farmas÷ytiske blandinger inneholdende dem
NO961888L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
DK0668769T3 (da) Egebarkekstrakt-relaterede syntetiske sammensætninger og fremgangsmåde til deres anvendelse
PT705100E (pt) Guanidinas substituidas terapeuticas
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
ATE277943T1 (de) Trypsininhibitoren
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
NO983906D0 (no) Anvendelse av karboniske anhydraseinhibitorer for behandling av makulær ödem
NO983295L (no) Kontroll av helingsprosess
AU3496295A (en) 2-substituted-4h-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement clr protease for the treatment of inflammatory processes
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
DE59107336D1 (de) Oligosaccharidderivate und deren Verwendung in Heilmitteln
IL111501A0 (en) Pharmaceutical compositions comprising lys-plasminogen and tissue plasminogen activator (t-PA) for the treatment of coronary thrombosis
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
ATE108655T1 (de) Topisch angebrachter goldorganokomplex.
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
GR3023046T3 (en) Transdermal therapeutic system with pentylene tetrazol as active substance.